Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – If aspirin is to be used routinely for primary prevention of cardiovascular disease, it should begin at age 48 in men and 57…
NEW YORK (Reuters Health) – Semen cryopreservation can be successfully performed in pubertal boys who are to undergo gonadotoxic cancer treatment, according to a report in the October…
NEW YORK (Reuters Health) – Patients hospitalized with bacterial pneumonia are nearly eight times more likely to experience an acute coronary syndrome (ACS) within 15 days of admission…
NEW YORK (Reuters Health) – The pregnancy, delivery, and implantation rates seen with frozen embryo donation in the US compare well with those reported with autologous in vitro…
NEW YORK (Reuters Health) – The platelet inhibition caused by clopidogrel is reduced when the drug is coadministered with calcium-channel blockers, Austrian researchers report. Dr. Bernd Jilma and…
NEW YORK (Reuters Health) – The US Food and Drug Administration has issued an alert about complications related to transvaginal placement of surgical mesh devices used to repair…
Sermo founder and CEO Daniel Palestrant, MD, talks about his website’s new partnership with Bloomberg at the Health 2.0 Conference in San Francisco, CA. For more information, visit:…
NEW YORK (Reuters Health) – An infusion of dexamethasone-loaded autologous erythrocytes appears to be an effective treatment for mild-to-moderate ulcerative colitis that is refractory to mesalamine, new research…
NEW YORK (Reuters Health) – Beta-blocker-induced heart rate lowering has been shown to have beneficial effects in patients with MI and heart failure, but findings from a new…
NEW YORK (Reuters Health) – As a treatment for early multiple sclerosis, alemtuzumab, an antibody that targets CD52 on lymphocytes and monocytes, is more effective than interferon beta-1a,…
